Dulaglutide Can Cause Falsely Elevated Pancreatic Cancer Markers — Don't Panic, Just Stop the Drug
A woman on dulaglutide for 16 months developed markedly elevated CA19-9 and CA242 tumor markers that normalized within 6 weeks of stopping the drug, with no underlying cancer found.
Quick Facts
What This Study Found
Dulaglutide caused significant elevation of serum CA19-9 and CA242 levels in an asymptomatic patient, which completely normalized within 6 weeks of drug discontinuation.
Key Numbers
Mid-60s female, dulaglutide for 16 months. Elevated CA19-9 and CA242 resolved after stopping.
How They Did This
Single case report with clinical workup including imaging and interventional assessments to exclude malignancy, followed by dulaglutide discontinuation and marker monitoring.
Why This Research Matters
As GLP-1 drugs become increasingly common, clinicians will encounter more patients with unexplained elevated tumor markers. Knowing that dulaglutide can cause this effect could prevent unnecessary invasive procedures, reduce patient anxiety, and save healthcare resources.
The Bigger Picture
This case adds to growing awareness of unexpected effects from GLP-1 receptor agonists. As these drugs are prescribed to millions, rare adverse effects and drug-biomarker interactions become increasingly important for clinical practice. Cancer screening protocols may need to account for GLP-1 drug use.
What This Study Doesn't Tell Us
Single case report — cannot determine how common this effect is. The mechanism by which dulaglutide elevates these markers was not investigated. It's unclear whether other GLP-1 drugs cause similar marker elevations.
Questions This Raises
- ?Do other GLP-1 receptor agonists (semaglutide, liraglutide) similarly elevate CA19-9 and CA242?
- ?What is the mechanism by which dulaglutide causes tumor marker elevation?
- ?Should patients on GLP-1 drugs receive modified cancer screening protocols?
Trust & Context
- Key Stat:
- 6 weeks to normalization CA19-9 and CA242 levels returned to normal after discontinuing dulaglutide, with no cancer found
- Evidence Grade:
- Preliminary evidence from a single case report. Demonstrates a clear temporal association but cannot establish how common this effect is.
- Study Age:
- Published in 2024. Relevant as GLP-1 drug prescriptions continue to surge worldwide.
- Original Title:
- Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.
- Published In:
- BMJ case reports, 17(5) (2024)
- Authors:
- Shi, Xiaomin
- Database ID:
- RPEP-09255
Evidence Hierarchy
Frequently Asked Questions
What are CA19-9 and CA242, and why are elevated levels concerning?
CA19-9 and CA242 are proteins that can be elevated in the blood when pancreatic, biliary, or gastrointestinal cancers are present. Finding high levels typically prompts an urgent cancer workup, but as this case shows, medications like dulaglutide can also cause elevations without any cancer.
Should I stop taking dulaglutide if I have elevated tumor markers?
Talk to your doctor. This case suggests that discontinuing dulaglutide and rechecking markers in a few weeks is a reasonable first step before pursuing invasive testing — but only your doctor can evaluate your complete clinical picture.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09255APA
Shi, Xiaomin. (2024). Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.. BMJ case reports, 17(5). https://doi.org/10.1136/bcr-2023-257657
MLA
Shi, Xiaomin. "Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.." BMJ case reports, 2024. https://doi.org/10.1136/bcr-2023-257657
RethinkPeptides
RethinkPeptides Research Database. "Significant elevation of serum CA19-9 and CA242 levels induc..." RPEP-09255. Retrieved from https://rethinkpeptides.com/research/shi-2024-significant-elevation-of-serum
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.